Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2017 Jan;96(1):e5781.
doi: 10.1097/MD.0000000000005781.

No further gain can be achieved by calculating Disease Activity Score in 28 joints with high-sensitivity assay of C-reactive protein because of high intraindividual variability of C-reactive protein: A cross-sectional study and theoretical consideration

Affiliations
Observational Study

No further gain can be achieved by calculating Disease Activity Score in 28 joints with high-sensitivity assay of C-reactive protein because of high intraindividual variability of C-reactive protein: A cross-sectional study and theoretical consideration

Inger M J Hansen et al. Medicine (Baltimore). 2017 Jan.

Abstract

Disease Activity Score in 28 joints (DAS28) is commonly used to evaluate disease activity of rheumatoid arthritis (RA) and is a guide to treatment decision.The aim of this study was to evaluate the impact of lower reporting limit for C-reactive protein (CRP), with respect to intraindividual biological variability, on the calculation of DAS28 and subsequent patient classification.This study consists of 2 sections: a theoretical consideration discussing the performance of CRP in calculating DAS28 taking intraindividual biological variation and lower reporting limit for CRP into account and a cross-sectional study of RA patients applying our theoretical results. Therefore, we calculated DAS28 twice, with the actual CRP values and CRP = 9 mg/L, the latter to elucidate the positive effects of reducing the lower reporting limit of CRP from <10 to <3 mg/L.Lower-reporting limit of <10 mg/L leads to overestimate DAS28. However, reducing lower reporting limit for CRP to <3 mg/L results in optimizing DAS28 calculation. Further lowering of reporting limit for CRP to <3 mg/L does not increase the precision of DAS28 owing to the relatively large intraindividual biological variation.Five hundred twelve patients were included. There was a significant difference between recalculated and patients DAS28 (P < 0.001). One hundred nine patients had DAS28 deviation (compatible to remission to low: 66, low to moderate: 39. and moderate to high: 4).Owing to significant impact of intraindividual biologic variation on DAS28 and patient classification, special attention should be paid to calculate DAS28 when CRP values are within normal range. Furthermore, we conclude that results of different studies evaluating DAS28 and treatment response are not comparable if the reporting limits of CRP are unknown.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

Figures

Figure 1
Figure 1
(A) The relation between DAS28 and CRP, when CRP ranging from 0 to 100 and other parameters were held constant (Tender joint = 0, Swollen joint = 0, and patient global assessment = 0). (B) Dependency of DAS28 to CRP (theoretical consideration). Tender joint: 3, Swollen joint: 1, and patient global assessment: 34. CV-within: intraindividual biological variation. DAS28 = Disease Activity Score in 28 joints, CRP = C-reactive protein.
Figure 2
Figure 2
Changes in patients’ disease activity when DAS28 calculated with CRP = 9 mg/L. DAS28 = Disease Activity Score in 28 joints, CRP = C-reactive protein.

References

    1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903–11. - PubMed
    1. Vander Cruyssen B, Van Looy S, Wyns B, et al. DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther 2005;7:R1063–71. - PMC - PubMed
    1. Van Riel PL. The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28). Clin Exp Rheumatol 2014;32:65–74. - PubMed
    1. Nielung L, Christensen R, Danneskiold-Samsøe B, et al. Validity and agreement between the 28-Joint Disease Activity Score based on C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. Arthritis 2015;2015:401690. - PMC - PubMed
    1. Inoue E, Yamanaka H, Hara M, et al. Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis 2007;66:407–9. - PMC - PubMed

Publication types

Substances